Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis.

Abstract

The fourth-generation 8-methoxyfluoroquinolone moxifloxacin is available as an 0.5% ophthalmic solution for use in the treatment of bacterial conjunctivitis. Moxifloxacin had good activity against various Gram-positive and -negative ocular isolates in vitro, and moxifloxacin 0.5% ophthalmic solution achieved good penetration into ocular tissues in healthy volunteers and patients undergoing ocular surgery. The efficacy of moxifloxacin 0.5% ophthalmic solution in the treatment of bacterial conjunctivitis has been shown in three randomized, double-blind, multicentre trials. In a trial in patients aged ≥1 year, the clinical success rate was significantly higher with moxifloxacin 0.5% ophthalmic solution than with placebo. In a trial in patients aged ≥12 years, moxifloxacin 0.5% ophthalmic solution was noninferior to levofloxacin 0.5% ophthalmic solution in terms of the clinical success rate. In a third trial, the clinical cure rate was significantly higher with moxifloxacin 0.5% ophthalmic solution than with trimethoprim 1.0%/polymixin B 10,000 IU/mL ophthalmic solution in paediatric patients aged ≤18 years. Moxifloxacin 0.5% ophthalmic solution was well tolerated in patients with bacterial conjunctivitis. Ocular adverse events (e.g. eye pain, eye irritation) were the most commonly reported treatment-related adverse events, with the majority being of mild severity.

• Authors: Gillian M Keating
• Journal: Drugs (Drugs) Vol. 71 Issue 1 Pg. 89-99 (Jan 01 2011) ISSN: 1179-1950 [Electronic] New Zealand
• PMID: 21175242 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Bacterial Agents
• Aza Compounds
• Fluoroquinolones
• Ophthalmic Solutions
• Quinolines
• Moxifloxacin

Topics

• Anti-Bacterial Agents (administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
• Aza Compounds (administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
• Clinical Trials as Topic
• Conjunctivitis, Bacterial (drug therapy, microbiology)
• Eye (drug effects)
• Fluoroquinolones
• Humans
• Moxifloxacin
• Multicenter Studies as Topic
• Ophthalmic Solutions
• Quinolines (administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
• Randomized Controlled Trials as Topic